Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjects

Journal of Clinical Pharmacology

Volumn 45, Issue 10, 2005, Pages 1172-1178

  Jermany, J ^a   Branson, J ^b   Schmouder, R ^b   Guillaume, M ^c   Rordorf, Christiane ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Aster   (France)

Author keywords

Aggregation; Aspirin; Lumiracoxib; Platelet

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; COLLAGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; LUMIRACOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTACYCLIN; THROMBOXANE B2;

ABDOMINAL PAIN; ADULT; ARTICLE; BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ENZYME IMMUNOASSAY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PROTECTION; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; NAUSEA; NORMAL HUMAN; OSTEOARTHRITIS; PHARMACODYNAMICS; PROSTAGLANDIN METABOLISM; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; URINALYSIS; VOLUNTEER; VOMITING;

ADOLESCENT; ADULT; ARACHIDONIC ACID; ASPIRIN; COLLAGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; EPOPROSTENOL; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANIC CHEMICALS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOXANE B2;

EID: 25444446582     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005280377     Document Type: Article

References (40)

1. Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002;4:R5.
2. Haara MM, Manninen P, Kroger H, et al. Osteoarthritis of finger joints in Finns aged 30 or over: prevalence, determinants, and association with mortality. Ann Rheum Dis. 2003;62:151-158.
3. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62:1145-1155.
4. Patrono C. Aspirin as an antiplatelet drug. N Engl J Med. 1994;330:1287-1294.
5. Lauer MS. Clinical practice: aspirin for primary prevention of coronary events. N Engl J Med. 2002;346:1468-1474.
6. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
7. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet. 2003;361:573-574.
8. Kimmel SE, Strom BL. Giving aspirin and ibuprofen after myocardial infarction. Br Med J. 2003;327:1298-1299.
9. Pairet M, Engelhardt G. Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundam Clin Pharmacol. 1996;10:1-17.
10. Mengle-Gaw LJ, Schwartz BD. Cyclo-oxygenase inhibitors: promise or peril? Mediat Inflamm. 2002;11:275-286.
11. Hernandez-Diaz S, Garcia Rodriguez LA. Epidemiological assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med. 2001;110(Suppl. 3A):20S-27S.
12. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med. 1999;340:1888-1899.
13. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232-235.
14. Roth GJ, Machuga ET, Ozols J. Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase. Biochemistry. 1983;22:4672-4675.
15. Baigent C, Patrono C. Selective cyclo-oxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. Arthritis Rheum. 2003;48:12-20.
16. Greenberg HE, Gottesdiener K, Huntington M, et al. A new cyclo-oxygenase inhibitor, rofecoxib (VIOXX) did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. J Clin Pharmacol. 2000;40:1509-1515.
17. Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J Clin Pharmacol. 2002;42:1027-1030.
18. Leese PT, Talwalker S, Kent JD, Recker DP. Valdecoxib does not impair platelet function. Am J Emerg Med. 2002;20:275-281.
19. Hartmann S, Scott G, Rordorf C, Campestrini J, Branson J, Keller U. Lumiracoxib demonstrates high absolute bioavailability in healthy subjects. In: Tulunay FC, Orme M, eds. European Collaboration: Towards Drug Development and Rational Drug Therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. Berlin: Springer-Verlag: 2003:124 (Abstract P-199).
20. Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metab Dispos. 2004;32:566-571.
21. Patrignani P, Campestrini J, Branson J, et al. Lumiracoxib is a selective inhibitor of cyclooxygenase-2 in patients with osteoarthritis (abstract FRI0412). Ann Rheum Dis. 2004;63(suppl I):368.
22. Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol. 2004;33:1-6.
23. Tannenbaum H, Berenbaum F, Reginster J-Y, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind study versus placebo and celecoxib. Ann Rheum Dis. 2004;63:1419-1426.
24. Geusens P, Alten R, Rovensky J, et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Int J Clin Pract. 2004;58:1033-1041.
25. Kellstein D, Ott D, Jayawardene S, Fricke J Jr. Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of postoperative dental pain. Int J Clin Pract. 2004;58:244-250.
26. Schnitzer TJ, Burmester GR, Mysler E, et al. TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364:665-674.
27. Born G. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962;194:927-929.
28. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000 23;343:1520-1528.
29. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA. 1999;96:272-277.
30. Dilger K, Herrlinger C, Peters J, Seyberth HW, Schweer H, Klotz U. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. J Clin Pharmacol. 2002;42:985-994.
31. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735-741.
32. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840-845.
33. FitzGerald G, Oates J, Hawigr J, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676-688.
34. Capone M, Tacconelli S, Scuilli M, et al. Clinical pharmacology of platelet, monocyte and vascular cyclooxygenase inhibition by naproxen and low dose aspirin in healthy subjects. Circulation. 2004;109:1468-1471.
35. Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol. 2004;24:246-225.
36. Scott G, Rordorf C, Reynolds C, et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet 2004;43:467-478.
37. Electronic Medicines Compendium Web site. Etoricoxib (Arcoxia) UK prescribing information. Available at: http://emc.medicines.org.uk. Accessed August 11, 2005.
38. Food and Drug Administration Web site. Rofecoxib (Vioxx) US prescribing information. Available at: http://www.fda.gov/cder/foi/label/2004/ 021052s026_021042s019lbl.pdf. Accessed August 11, 2005.
39. Food and Drug Administration Web site. Celecoxib (Celebrex) US prescribing information. Available at: http://www.fda.gov/cder/foi/label/2005/ 020998s018,019lbl.pdf. Accessed August 11, 2005.
40. Food and Drug Administration Web site. Valdecoxib (Bextra) US prescribing information. Available at: http://www.fda.gov/cder/foi/label/2004/ 21341se8003_bextra_lbl.pdf. Accessed August 11, 2005.